Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study.

Saved in:
Bibliographic Details
Title: Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study.
Authors: Jain H; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India., Karulkar A; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India., Kalra D; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India., Ravikumar S; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India., Shah S; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India., Firfiray A; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India., Pendhari J; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India., Jaiswal AK; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India., Khan A; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India., Sundharam M; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India., Vaibhaw A; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India., Saroha A; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India., Rajyopadhye S; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India., Basu M; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India., Asija S; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India., Chowdhury A; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India., Beher R; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India., Banik A; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India., Dwivedi A; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India., Purwar S; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India., Narula G; Department of Pediatric Oncology, Tata Memorial Centre, Mumbai, India., Banavali S; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India., Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Highfill SL; Transfusion Medicine Department, National Institute of Health Clinical Center, Bethesda, MD, USA., Stroncek D; Transfusion Medicine Department, National Institute of Health Clinical Center, Bethesda, MD, USA., Fry T; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD, USA; Hematology, Oncology and Bone Marrow Transplantation Section, Department of Pediatrics, University of Colorado Hospital, Children's Hospital Colorado, CO, USA., Melinkeri S; Deenanath Mangeshkar Hospital, Pune, Maharashtra, India., Wilson L; SMBT Hospital, Nashik, India., Agarwal N; Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India., Aribandi A; American Oncology Institute, Hyderabad, India., Boyella PK; Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, India., Shah NN; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD, USA., Neelapu SS; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sengar M; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India., Purwar R; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India. Electronic address: rahul.purwar@immunoact.com.
Corporate Authors: CAR-T clinical trial group
Source: The Lancet. Haematology [Lancet Haematol] 2025 Apr; Vol. 12 (4), pp. e282-e293. Date of Electronic Publication: 2025 Mar 13.
Publication Type: Journal Article; Clinical Trial, Phase I; Multicenter Study; Clinical Trial, Phase II
Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2352-3026
DOI:10.1016/S2352-3026(24)00377-6